title: Ambiguous genitalia--etiology, diagnosis, and therapy.
abstract: Patients with ambiguous genitalia stand a far better chance of receiving a rapid diagnosis, appropriate replacement therapy, and functional surgical reconstruction than was the case even a decade ago. Although the etiologies of true hermaphroditism and mixed gonadal dysgenesis remain elusive, most gene defects in female pseudohermaphroditism or CAH have been pinpointed to the 21-hydroxylase gene. Incomplete masculinization has been found to be due to defects in the androgen receptor, 5 alpha-reductase, or enzymes in the pathway from cholesterol to testosterone. SRY point mutations have been implicated in 46XY pure gonadal dysgenesis. Retained müllerian ducts have been attributed to point mutations in the MIS gene; those with normal MIS levels should be expected to have receptor deficits. In utero diagnoses and treatment and diagnosis at the preimplantation stage may prove to be very important for the care of some of these patients, who may be potential candidates for gene replacement therapy. When necessary, surgical reconstruction can be done. If the child is to be raised as a female, clitoral recession, labioscrotal reductions and advancements, and vaginoplasties for exteriorization can be accomplished in early infancy as an extensive one-stage procedure. If patients are to be raised as males, then various types of hypospadias repair can be done, gonads can be replaced with prostheses, the prepenile scrotum can be reconstructed, and müllerian structures can be removed with the goal of preserving the vas deferens. Replacement therapy with glucocorticoids and mineralocorticoids must be precisely managed to permit proper growth, and testosterone, estrogen, and progesterone replacement must be carefully considered and managed. A most important element in the care of these patients is the psychological support that first the families and then the patient require. This must be delivered with sensitivity. The proper care of these complex patients requires that the physician be a scientist as well as a clinician and a skilled technician.
authors.affiliation: Harvard Medical School, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.
authors.forename: D D
authors.initials: DD
authors.lastname: Federman
authors.forename: P K
authors.initials: PK
authors.lastname: Donahoe
mesh_terms: D001483:Base Sequence; D012734:Disorders of Sex Development / Q000175:diagnosis / Q000209:etiology / Q000628:therapy; D005260:Female; D005835:Genitalia / Q000002:abnormalities*; D005938:Glucocorticoids / Q000627:therapeutic use; D006059:Gonadal Dysgenesis / Q000175:diagnosis / Q000209:etiology / Q000628:therapy; D006801:Humans; D008297:Male; D008901:Mineralocorticoids / Q000627:therapeutic use; D008969:Molecular Sequence Data; D012733:Sex Differentiation / Q000502:physiology*
chemical_list: D005938:Glucocorticoids; D008901:Mineralocorticoids